Press "Enter" to skip to content

Roche-AbbVie cancer drug gets accelerated FDA approval

The drug, developed in partnership with AbbVie Inc, was approved for patients with acute myeloid leukemia (AML) aged 75 or older, or those ineligible for intensive induction chemotherapy.

Original source:

Also Read:   USFDA completes inspection of Strides Pharma's Alathur facility with zero observations